Aptar Pharma and Dianosic Announce Exclusive Partnership to Advance the Active Resorbable Intranasal Scaffold Platform for the Treatment of Chronic Allergic Rhinitis and Chronic Rhinosinusitis

▤ Summary

Aptar Pharma and Dianosic announced an exclusive partnership to develop an active resorbable intranasal scaffold platform for chronic allergic rhinitis and chronic rhinosinusitis. Aptar Pharma will invest in Dianosic, join its strategic committee, and help promote the technology to customers. The collaboration also explores nose-to-brain delivery opportunities in neuropsychiatric and neurodegenerative diseases. The companies aim to combine Dianosic’s clinical innovation with Aptar Pharma’s nasal drug-delivery expertise and services to bring the solution to market.

▦ Linked Companies